Balyasny Asset Management
OLMA icon

Balyasny Asset Management’s Olema Pharmaceuticals OLMA Stock Holding History

Balyasny Asset Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Sell
89,671
-77,637
-46% -$1.73M ﹤0.01% 1954
2025
Q4 		$4.18M Sell
167,308
-525,871
-76% -$9.36M 0.01% 1493
2025
Q3 		$6.79M Buy
+693,179
New +$4.16M 0.01% 1236
2025
Q2 		– Sell
-113,018
Closed -$425K – 3205
2025
Q1 		$425K Sell
113,018
-1,014,571
-90% -$5.1M ﹤0.01% 2335
2024
Q4 		$6.57M Buy
1,127,589
+418,492
+59% +$4.18M 0.01% 1140
2024
Q3 		$8.47M Buy
+709,097
New +$9.07M 0.01% 1034
2022
Q4 		– Sell
-12,097
Closed -$33K – 3096
2022
Q3 		$33K Buy
+12,097
New +$51.3K ﹤0.01% 2522

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Balyasny Asset Management's OLMA Position: Q1 2026 in Review

Balyasny Asset Management reduced its Olema Pharmaceuticals (OLMA) stake by 46% in Q1 2026, selling an estimated $1.73M and leaving 89,671 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1954.

Balyasny Asset Management first reported a position in OLMA in Q3 2022 and has held it in 7 quarters since. The position peaked at $8.47M in Q3 2024. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Balyasny Asset Management held 89,671 shares of Olema Pharmaceuticals worth $1.34M as of Q1 2026.
  • Balyasny Asset Management sold 77,637 Olema Pharmaceuticals shares in Q1 2026, an estimated $1.73M.
  • Olema Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1954 holding.
  • Balyasny Asset Management first reported a position in Olema Pharmaceuticals in Q3 2022 and has held it in 7 quarters since.
  • Balyasny Asset Management's Olema Pharmaceuticals position peaked at $8.47M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.